Hypoalphalipoproteinemia: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett |
||
| Line 2: | Line 2: | ||
==Treatment== | ==Treatment== | ||
Using [[gemfibrozil]] to treat hypoalphalipoproteinemia may reduce | Using [[gemfibrozil]] to treat hypoalphalipoproteinemia may reduce major cardiovascular events<ref name="pmid10438259">{{cite journal |author=Rubins HB, Robins SJ, Collins D, ''et al'' |title=Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group |journal=N. Engl. J. Med. |volume=341 |issue=6 |pages=410–8 |year=1999 |pmid=10438259 |doi= |issn=}}</ref> and [[stroke]]<ref name="pmid11401940">{{cite journal |author=Bloomfield Rubins H, Davenport J, Babikian V, ''et al'' |title=Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) |journal=Circulation |volume=103 |issue=23 |pages=2828–33 |year=2001 |pmid=11401940 |doi= |issn=}}</ref> and in men with known men with known [[coronary heart disease]]. | ||
Using [[simvastatin]] plus [[niacin]] to treat hypoalphalipoproteinemia may reduce cardiovascular event in men with [[coronary heart disease]].<ref name="pmid11757504">{{cite journal |author=Brown BG, Zhao XQ, Chait A, ''et al'' |title=Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease |journal=N. Engl. J. Med. |volume=345 |issue=22 |pages=1583–92 |year=2001 |pmid=11757504 |doi= |issn=}}</ref> | |||
==References== | ==References== | ||
Revision as of 16:50, 17 December 2007
Hypoalphalipoproteinemias, also called familial high density lipoprotein deficiency disease and HDL lipoprotein deficiency disease, are defined as "conditions with abnormally low levels of alpha-lipoproteins (high-density lipoproteins) in the blood. Hypoalphalipoproteinemia can be associated with mutations in genes encoding apolipoprotein a-i; lecithin cholesterol acyltransferase; and atp-binding cassette transporters."[1]
Treatment
Using gemfibrozil to treat hypoalphalipoproteinemia may reduce major cardiovascular events[2] and stroke[3] and in men with known men with known coronary heart disease.
Using simvastatin plus niacin to treat hypoalphalipoproteinemia may reduce cardiovascular event in men with coronary heart disease.[4]
References
- ↑ National Library of Medicine. Hypoalphalipoproteinemias. Retrieved on 2007-12-17.
- ↑ Rubins HB, Robins SJ, Collins D, et al (1999). "Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group". N. Engl. J. Med. 341 (6): 410–8. PMID 10438259. [e]
- ↑ Bloomfield Rubins H, Davenport J, Babikian V, et al (2001). "Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT)". Circulation 103 (23): 2828–33. PMID 11401940. [e]
- ↑ Brown BG, Zhao XQ, Chait A, et al (2001). "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease". N. Engl. J. Med. 345 (22): 1583–92. PMID 11757504. [e]